(JALSG論文をご発表の際は、必ず事務局までご報告下さい。)
【論文タイトル /// 全著者名 /// 掲載誌】 (2015/12/22更新)
JALSG論文集の掲載 【調整中】
JALSG論文集
128. Unrelated bone marrow transplantation or immediate umbilical cord blood
transplantation for patients with acute myeloid leukemia in first complete
remission./// Yanada M, Kanda J, Ohtake S, Fukuda T, Sakamaki H, Miyamura K,
Miyawaki S, Uchida N, Maeda T, Nagamura-Inoue T, Asou N, Morishima Y, Atsuta Y,
Miyazaki Y, Kimura F, Kobayashi Y, Takami A, Naoe T, Kanda Y.///
Eur J Haematol. 2015 Dec 18. [Epub ahead of print]
Results From a Randomized Controlled Trial. /// Shinagawa K, Yanada M,
Sakura T, Ueda Y, Sawa M, Miyatake J, Dobashi N, Kojima M, Hatta Y,
Emi N, Tamaki S, Gomyo H, Yamazaki E, Fujimaki K, Asou N, Matsuo K,
Ohtake S, Miyazaki Y, Ohnishi K, Kobayashi Y, Naoe T. /// J Clin Oncol.
10;33(2):228. 2015
126. Markedly improved outcomes and acceptable toxicity in adolescents and
young adults with acute lymphoblastic leukemia following treatment with
a pediatric protocol: a phase II study by the Japan Adult Leukemia Study
Group /// F Hayakawa, T Sakura, T Yujiri, E Kondo, K Fujimaki, O Sasaki,
J Miyatake, H Handa, Y Ueda, Y Aoyama, S Takada, Y Tanaka, N Usui,
S Miyawaki, S Suenobu, K Horibe, H Kiyoi, K Ohnishi, Y Miyazaki. S Ohtake,
Y Kobayashi, K Matsuo and T Naoe for the Japan Adult Leukemia Study
Group(JALSG) /// Blood Cancer Journal(2014) 4, e252
125. Delayed hematopoietic recovery after auto-SCT in patients receiving arsenic
trioxide-based therapy for acute promyelocytic leukemia: a multi-center analysis.
/// Mannis GN, Logan AC, Leavitt AD, Yanada M, Hwang J, Olin RL, Damon LE,
Andreadis C, Ai WZ, Gaensler KM, Greene CC, Gupta NK, Kaplan LD,
Mahindra A, Miyazaki Y, Naoe T, Ohtake S, Sayre PH, Smith CC, Venstrom JM,
Wolf JL, Caballero L, Emi N, Martin TG./// Bone Marrow Transplant. 2014 Sep 22.
[Epub ahead of print]
124. Comprehensive analysis of genetic alterations and their prognostic impacts
in adult acute myeloid leukemia patients. /// Kihara R, Nagata Y, Kiyoi H,
Kato T, Yamamoto E, Suzuki K, Chen F, Asou N, Ohtake S, Miyawaki S,
Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Kiguchi T, Imai K,
Uike N, Kimura F, Kitamura K, Nakaseko C, Onizuka M, Takeshita A, Ishida F,
Suzushima H, Kato Y, Miwa H, Shiraishi Y, Chiba K, Tanaka H, Miyano S,
Ogawa S, Naoe T./// Leukemia. 28(8):1586-95. 2014
123.Normal karyotype acute myeloid leukemia with the CD7+ CD15+
CD34+ HLA-DR + immunophenotype is a clinically distinct entity
with a favorable outcome./// Iriyama N, Asou N, Miyazaki Y, Yamaguchi S,
Sato S, Sakura T, Maeda T, Handa H, Takahashi M, Ohtake S, Hatta Y,
Sakamaki H, Honda S, Taki T, Taniwaki M, Miyawaki S, Ohnishi K,
Kobayashi Y, Naoe T./// Ann Hematol. 93(6): 957-63. 2014
122. CD56 expression is an independent prognostic factor for relapse in acute
myeloid leukemia with t(8;21)./// Iriyama N, Hatta Y, Takeuchi J, Ogawa Y,
Ohtake S, Sakura T, Mitani K, Ishida F, Takahashi M, Maeda T, Izumi T,
Sakamaki H, Miyawaki S, Honda S, Miyazaki Y, Taki T, Taniwaki M, Naoe T.
/// Leuk Res. 2013 Sep;37(9):1021-6.
121.Role of hematopoietic stem cell transplantation for relapsed
acute promyelocytic leukemia: a retrospective analysis of JALSG-
APL97. /// Fujita H, Asou N, Iwanaga M, Hyo R, Nomura S, Kiyoi H,
Okada M, Inaguma Y, Matsuda M, Yamauchi T, Ohtake S, Izumi T,
Nakaseko C, Ishigatsubo Y, Shinagawa K, Takeshita A, Miyazaki Y,
Ohnishi K, Miyawaki S, Naoe T; Japan Adult Leukemia Study Group.
/// Cancer Sci. 2013 Oct;104(10):1339-45.
120.The demarcation between younger and older acute myeloid
leukemia patients: a pooled analysis of 3 prospective studies.
/// Yanada M, Ohtake S, Miyawaki S, Sakamaki H, Sakura T, Maeda
T, Miyamura K,Asou N, Oh I, Miyatake J, Kanbayashi H, Takeuchi
J, Takahashi M, Dobashi N, Kiyoi K, Miyazaki Y, Emi N,Kobayashi Y,
Ohno R, Naoe T/// Cancer. 119(18): 3326-33. 2013
119.Phase 2 study of arsenic trioxide followed by autologous
hematopoietic cell transplantation for relapsed acute
promyelocytic leukemia./// Yanada M, Tsuzuki M, Fujita H, Fujimaki
K, Fujisawa S,Sunami K,Taniwaki M, Ohwada A, Tsuboi K, Maeda
A, Takeshita A, Ohtake S, Miyazaki Y, AtsutaY, Kobayashi Y, Naoe
T, Emi N/// Blood. 121:3095-3102.2013
118.Clinical studies of acute myeloid leukemia in the Japan Adult Leukemia
Study Group./// S Miyawaki /// Int J Hematol. Aug;96(2):171-7. 2012
117.Phase 1 trial of gemtuzumab ozogamicin in combination with
enocitabine and daunorubicin for elderly patients with relapsed or
refractory acute myeloid leukemia: Japan Adult Leukemia Study
Group (JALSG)-GML208 study./// Y Ito, A Wakita, S Takada, M
Mihara, M Gotoh, K Ohyashiki, S Ohtake, S Miyawaki, K Ohnishi, O
Naoe/// Int J Hematol 96(4):485-91.2012
116.Long-term outcome and prognostic factors of elderly patients with
acute promyelocytic leukemia./// T Ono, A Takeshita, U Kishimoto,
H Kiyoi, M Okada, T Ymauchi, M Tsuzuki, K Horikawa, M Matuda, K
Shinagawa, F Monma, S Ohtake, C Nakaseko, M Takahashi, U
Kimura,M Iwanaga, N Asou, adn O Naoe for the Japan Adult
Leukemia Study Group/// Cancer Sci 103(11):1974-8. 2012
115.Randomized comparison of fixed-schedule versus response-
oriented individualized induction therapy and use of ubenimex
during and after consolidation therapy for eldery patients with
acute myeloid leukemia:the JALSG GML200 Study/// A wakita, H
Ohteke, S Takada, F Yagasaki, H Komatsu, Y Miyazaki, et al./// Int
J Hematol 96(4):485-91. 2012
114.Long-term outcome following imatinib therapy for chronic
myelogenous leukemia, with assessment of dosage and blood levels:
the JALSG CML202 study/// K Ohnishi, C Nakaseko, J takeuchi, S
Fujisawa, T Nagai, H Yamazaki, T Tauchi, K Imai, N Mori, F Yagasaki,
Y Maeda, N Usui, Y Miyazaki, K Miyamura, H Kiyoi, H Ohtake, T
Naoe and for the Japan Adult Leukemia Study Group/// Cancer
Sci 103;1071-1078. 2012
113.Impact of additional chromosomal abnormalities in patients with
acute promyelocytic leukemia:10-year results of the Japan Adult
Leukemia Study Group APL97 study./// T Ono, A Takeshita, M
Iwanaga, N Asou, T Naoe, and R Ohno for he Japan Adult
Leukemia Study Group/// Haematologica 96(1);174-175, 2011
112.Phase I trial of gemtuzumab ozogamicin in intensive combination
chemotherapy for relapsed or refractory adult acute myeloid
leukemia(AML):Japan Adult Leukemia Study
Group(JALSG)-AML206 study./// N Usui, A Takeshita, C
Nakaseko, N Dobashi, H Fujita, H Kiyoi, Y Kobayashi, T Sakura, Y
Yahagi, K Shigeno, C Ohwada, Y Miyazaki, S Ohtake, S Miyawaki, T
Naoe and K Ohnishi for the Japan Adult Leukemia Study
Group/// Cancer Science 2011;102:1358-65.
111.A decision analysis of allogeneic hematopoietic stem cell
transplantation in adult patients with Philadelphia chromosome-
negative acute lymphoblastic leukemia in first remission who have
an HLA-matced sibling donor.///S Kako, S Morita, H Sakamaki, H
Ogawa, T Fukuda, S Takahashi, H Kanamori, M Onizuka, K Iwato, R
Suzuki, Y Atsuta, T kyo, T Sakura, I Jinnai, J akeuchi, Y Miyazaki, S
Miyawaki, K Ohnishi, T Naoe and Y Kanda///Leukemia 25:259-265.
2011
110.Analysis of bacteremia/fungemia and pneumonia accompanying
acute myelogenous leukemia from 1987 to 2001 in the Japan Adult
Leukemia Study Group. ///Yoshida M, Akiyama N, Fujita H, Miura
K, Miyatake J, Handa H, Kito K, Takahashi M, Shigeno K, Kanda Y,
Hatsumi N, Ohtake S, Sakamaki H, Ohnishi K, Miyawaki S, Ohno R,
Naoe T./// Int J Hematol. 93:66-73. 2011
109.Pre-transplant imatinib-based therapy improves the outcome of
allogeneic hematopoietic stem cell transplantation for BCR-ABL-
positive acute lymphoblastic leukemia.///Mizuta S, Matsuo K,
Yagasaki F, Yujiri T, Hatta Y, Kimura Y, Ueda Y, Kanamori H, Usui
N, Akiyama H, Miyazaki Y, Ohtake S, Atsuta Y, Sakamaki H, Kawa
K, Morishima Y, Ohnishi K, Naoe T, Ohno R.///Leukemia25 :41-7.
2011
108.BCR-ABL1 mutations in patients with imatinib-resistant
Philadelphia chromosome-positive leukemia by use of the
PCR-Invader assay.///Ono T, Miyawaki S, Kimura F, Kanamori H,
Ohtake S, Kitamura K, Fujita H, Sugiura I, Usuki K, Emi N, Tamaki
S, Aoyama Y, Kaya H, Naoe T, Tadokoro K, Yamaguchi T, Ohno R,
Ohnishi K; for the Japan Adult Leukemia Study Group.///Leuk
Res 35:598-603. 2011
107.Randomized study of induction therapy comparing standard-dose
idarubicin with high-dose daunorubicin in adult patients with
previously untreated acute myeloid leukemia: JALSG AML201
Study.///Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K,
Usui N, Okumura H, Miyamura K, Nakaseko C, Miyazaki Y, Fujieda
A, Nagai T, Yamane T, Taniwaki M, Takahashi M, Yagasaki F, Kimura
Y, Asou N, Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T,
Ohno R.///Blood. 2011;117:2358-2365.
106.A randomized comparison of four courses of standard-dose
multiagent chemotherapy versus three courses of high-dose
cytarabine alone in post-remission therapy for acute myeloid
leukemia in adults: the JALSG AML201 study.///Miyawaki S,
Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, Sakura T,
Miyamura K, Nakaseko C, Miyazaki Y, Fujieda A, Nagai T, Yamane
T, Taniwaki M, Takahashi M, Yagasaki F, Kimura Y, Asou N,
Sakamaki H, Handa H, Honda S, Ohnishi K, Naoe T, Ohno
R.///Blood 117:2366-2372. 2011
105.Prognostic petential of detection of WT1 mRNA level in peripheral
bolld in adult acute myeloid leukemia.///S Miyawaki, N Hatsumi, T
Tamaki, T Naoe, K Ozawa, K Kitamura, T Karasuno, K Mitani, Y
Kodera, T Yamagami, D Koga.///Leukemia & Lymphoma
51:1855-1861. 2010
104.Intensified consolidation therapy with dose-escalated doxorubicin
did not improve the prognosis of adults with acute lymphoblastic
leukemia: the JALSG-ALL97 study.///Jinnai I, Sakura T, Tsuzuki
M, Maeda Y, Usui N, Kato M, Okumura H, Kyo T, Ueda Y, Kishimoto
Y, Yagasaki F, Tsuboi K, Horiike S, Takeuchi J, Iwanaga M, Miyazaki
Y, Miyawaki S, Ohnishi K, Naoe T, Ohno R.///Int J Hematol. 2010
;92:490-502.
103.Allogeneic stem cell transplantation versus chemotherapy as
post-remission therapy for intermediate or poor risk adult acute
myeloid leukemia: results of the JALSG AML97 study.///Sakamaki
H, Miyawaki S, Ohtake S, Emi N, Yagasaki F, Mitani K, Matsuda S,
Kishimoto Y, Miyazaki Y, Asou N, Takahashi M, Ogawa Y, Honda S,
Ohno R.///Int J Hematol. 2010 ;91:284-92.
102.Comparative analysis of remission induction therapy for high-risk
MDS and AML progressed from MDS in the MDS200 study of
Japan Adult Leukemia Study Group///Morita Y, Kanamaru A,
Miyazaki Y, Imanishi D, Yagasaki F, Tanimoto M, Kuriyama K,
Kobayashi T, Imoto S, Ohnishi K, Naoe T, Ohno R.///Int J Hematol
91:97-103. 2010
101.Randomized trial of response-oriented individualized versus fixed-
schedule induction chemotherapy with idarubisin and cytarabine in
adult acute myeloid leukemia: the JALSG AML95 study.///Ohtake
S, Miyawaki S, Kiyoi H, Miyazaki Y, Okumura H, Matsuda S, Nagai T,
Kishimoto Y, Okada M, Takahashi M, Handa H, Takeuchi J,
Kageyama S, Asou N, Yagasaki F, Maeda Y, Ohnishi K, Naoe T,
Ohno R./// Int J Hematol91:276-83. 2010
100.Diagnosis and management of acute myeloid leukemia in adults:
recommendations from an international expert panel, on behalf of
the European LeukemiaNet. ///Dohner H, Estey EH, Amadori S,
Appelbaum FR, Buchner T, Burnett AK, Dombret H, Fenaux P,
Grimwade D, Larson RA, Lo Coco F, Naoe T, Niederwieser D,
Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Lowenberg B,
Bloomfield CD.///Blood 21;115(3):453-74. 2010
99.Recent advances in the treatment of Philadelphia chromosome-
positive acute lymphoblastic leukemia.///Yanada M, Ohno R, Naoe
T.///Int J Hematol. 89:3-13.2009
98.Phase 1/2 clinical study of dasatinib in Japanese patients with
chronic myeloid leukemia or Philadelphia chromosome-positive
acute lymphoblastic leukemia.///Sakamaki H, Ishizawa K, Taniwaki
M, Fujisawa S, Morishima Y, Tobinai K, Okada M, Ando K, Usui N,
Miyawaki S, Utsunomiya A, Uoshima N, Nagai T, Naoe T, Motoji T,
Jinnai I, Tanimoto M, Miyazaki Y, Ohnishi K, Iida S, Okamoto S,
Seriu T, Ohno R.///Int J Hematol. 89:332-41. 2009
97.Phase I/II study of humanized anti-CD33 antibody conjugated with
calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory
acute myeloid leukemia: final results of Japanese multicenter
cooperative study.///Kobayashi Y, Tobinai K, Takeshita A, Naito K,
Asai O, DObahsi N, Furusawa S, Saito K, Mitani K, Morishima Y,
Ogura M, Yoshiba F, Hotta T, Bessho M, Matsuda S, Takeuchi J,
Miyawaki S, Naoe T, Usui N, Ohno R./// Int J Hematol. 2009; 89:
460-9.
96.Management of infection in patients with acute leukemia during
chmotherapy in Japan: questionnaire analysis by the Japan Adult
Leukemia Study Group///Fujita H, Yoshida M, Miura K, Sano T,
Kito K, Takahashi M, Shigeno K, Kanda Y, Akiyama N, Hatsumi N,
Ohnishi K, Miyawaki S, Naoe T.///In J Hematol.90:191-198.2009
95.Management of acute promyelocytic leukemia: recommendations
from an expert panel on behalf of the European
LeukemiaNet.///Sanz MA, Grimwade D, Tallman MS, Lowenberg B,
Fenaux P, Estey EH, Naoe T,Lengfelder E, Buchner T, Dohner H,
Burnett AK, Lo-Coco F.///Blood. 113(9):1875-91. 2009
94.Prospective monitoring of BCR-ABL1 transcript levels in patients
with Philadelphia chromosome-positive acute lymphoblastic
leukaemia undergoing imatinib-combined chemotherapy./// Yanada
M, Sugiura I, Takeuchi J, Akiyama H, Maruta A, Ueda Y, Usui N,
Yagasaki F, Yujiri T, Takeuchi M, Nishii K, Kimura Y, Miyawaki S,
Narimatsu H, Miyazaki Y, Ohtake S,Jinnai I, Matsuo K, Naoe T,
Ohno R for the Japan Adult Leukemia Study Group.///Brit J
Haematol.143:503-510.2008
93.Diagnosis of acute myeloid leukemia according to the WHO
classification in the Japan Adult Leukemia Study Group AML-97
protocol.///Wakui M, Kuriyama K, Miyazaki Y, Hata T, Taniwaki M,
Ohtake S, Sakamaki H, Miyawaki S, Naoe T, Ohno R, Tomonaga
M.///Int J Hematol 87:144-151.2008
92.Karyotype at diagnosis is the major prognostic factor predicting
relapse-free survival for patients with Philadelphia chromosome-
positive acute lymphoblastic leukemia treated with imatinib-
combined chemotherapy.///M Yanada, J Takeuchi, I Sugiura, H
Akiyama, N Usui, F Yagasaki, K Nishii, Y Ueda,M Takeuchi, S
Miyawaki, A Maruta, H Narimatsu, Y Miyazaki, S Ohtake, I Jinnai, K
Matsuo, T Naoe, R Ohno, for the Japan Adult Leukemia Study
Group.///Haematologica 93:287-290. 2008
91.Phase I Traial of FLAGM with High Doses of Cytosine Arabinoside
for Relapsed, Refractory Acute Myeloid Leukemia: Study of the
Japan Adult Leukemia Study Group(JALSG)///Miyawaki S, Kawai
Y, Takeshita A, Komatsu N, Usui N, Arai Y, Ishida F, Morii T, Kano
Y, Ogura M, Doki N, Ohno R.///In J Hematol. 86: 343-347.2007
90.A randomized study with or without intensified maintenance
chemotherapy in patients with acute promyelocytic leukemia who
have become negative for PML-RARα transcript after
consolidation therapy:The Japan Adult Leukemia Study
Group(JALSG) APL97 study./// Asou N, Kishimoto Y, Kiyoi H,
Okada M, Kawai Y, Tsuzuki M, Horikawa K, Matsuda M, Shinagawa
K, Kobayashi T, Ohtake S, Nishimura M, Takahashi M, Yagasaki F,
Takeshita A, Kimura Y, Iwanaga M, Naoe T, and Ohno R, for the
Japan Adult Leukemia Study Group///Blood 110:59-66. 2007
89.Prediction of risk of disease recurrence by genome-wide cDNA
microarryay analysis in patioents with Philadelphia chromosome-
positive acute lymphoblastic leukemia treated with imatinib-
combined cnemotherapy.///Zembutsu H, Yanada M, Hishida A,
Katagiri T, Tsuruo T, Sugiura I, Takeuchi J, Usui N, Naoe T,
Nakamura Y, Ohno R.///Int J Oncol. 31:313-22.2007
88.Severe hemorrhagic complications during remission induction
therapy for acute promyelocytic leukemia: incidence, risk factors,
and influence on outcome.///Yanada M, Matsushita T, Asou N,
Kishimoto Y, Tsuzuki M, Maeda Y, Horikawa K, Okada M, Ohtake S,
Yagasaki F, Matsumoto T, Kimura Y, Shinagawa K, Iwanaga M,
Miyazaki Y, Ohno R, Naoe T.///Eur J Haematol. 78(3):213-9.2007
87.Clinical features and outcome of T-lineage acute lymphoblastic
leukemia in adults: a low initial white blood cell count, as well as a
high count predict decreased survival rates.///Yanada M, Jinnai I,
Takeuchi J, Ueda T, Miyawaki S, Tsuzuki M, Hatta Y, Usui N, Wada
H, Morii T, Matsuda M, Kiyoi H, Okada M, Honda S, Miyazaki Y,
Ohno R, Naoe T./// Leuk Res 31(7):907-14.2007
86.Imatinib combined chemotherapy for Philadelphia chromosome-
positive acute lymphoblastic leukemia: major challenges in current
practice.///Yanada M, Naoe T.///Leuk & Lymph.Y 47:1747-1753,
2006.
85.High Complete Remission Rate and Promising Outcome by
Combination of Imatinib and Chemotherapy for Newly Diagnosed
BCR-ABL-positive Acute Lymphoblastic Leukemia: A Phase 2
Study by the Japan Adult Leukemia Study Group. ///Yanada M,
Takeuchi J, Sugiura I, Akiyama H, Usui N, Yagasaki F,Kobayashi T,
Ueda Y, Takeuchi M, Miyawaki S, Maruta A, Emi N, Miyazaki
Y,Ohtake S, Jinnai I, Matsuo K, Naoe T, and Ohno R./// J Clin
Oncol.24:460 -466. 2006
84.A Randomized, Postremission Comparison of Four Courses of
Standard-Dose Consolidation Therapy without Maintenance
Therapy versus Three Courses of Standard-Dose Consolidation
with Maintenance Therapy in Adults with Acute Myeloid Leukemia:
The Japan Adult Leukemia Study Group AML97 Study///
Miyawaki S, Sakamaki H, Ohtake S, Emi N, Yagasaki F, Mitani
K, Matsuda S, Kishimoto Y, Miyazaki Y, Asou N, Matsushima T,
Takahashi M, Ogawa Y, Honda S, Ohno R,and for the Japan
Adult Leukemia Study Group///Cancer 104. 2726 -34. 2005
83.Clinical characteristics and prognostic implications of NPM1
mutations in acute myeloid leukemia. ///Suzuki T, Kiyoi H, Ozeki K,
Tomita A, Yamaji S, Suzuki R, Kodera Y, Miyawaki S, Asou N,
Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Nishimura M,
Motoji T, Shinagawa K, Takeshita A, Ueda R, Kinoshita T, Emi N,
Naoe T. ///Blood 106: 2854-2861. 2005
82.A randomized study with or without maintenance/intensification
chemotherapy in newly diagnosed patients with acute
promyelocytic leukemia: the JALSG APL97 study. /// Naoe T,
Asou N, Ohno R for the Japan Adult Leukemia Study Group
(JALSG). ///Haematologica reports 1: 70-71. 2005
81.Comparison of graft-versus-host-disease and survival after
HLA-identical sibling bone marrow transplantation in ethnic
populations./// Hakumei Oh, Fausto R. Loberiza, Jr, Mei-jie Zhang,
Olle Ringden, Hideki Akiyama, Takayoshi Asai, Shuichi Miyawaki,
Shinichiro Okamoto, Mary M. Horowitz, Joseph H. Antin, Asad
Bashey, Jennifer M. Bird, Matthew H. Carabasi, Joseph W. Fay,
Robert Peter Gale, Roger H. Giller, John M. Goldman, Gregory A.
Hale, Richard E. Harris, Jean Henslee-Downey, Hans-Jochem Kolb,
Mark R. Litzow, Philip L. McCarthy, Steven M. Neudorf, Derek S.
Serna, Gerard Socie, Pierre Tiberghien, and A. John
Barrett///Blood 105(4):1408-1416. 2005
80.Biological and clinical significance of the FLT3 transcript level in
acute myeloid leukemia./// Ozeki K, Kiyoi H, Hirose Y, Iwai M,
Ninomiya M, Kodera Y, Miyawaki S, Kuriyama K, Shimazaki C,
Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda
R, Ohno R, Emi N, Naoe T./// Blood. 103:1901-1908. 2004
79.Combination of intensive chemotherapy and imatinib can rapidly
induce high-quality complete remission for a majority of patients
with newly diagnosed BCR-ABL positive acute lymphoblastic
leukemia.///Towatari M, Yanada M, Usui N, Takeuchi J, Sugiura I,
Takeuchi M, Yagasaki F, Kawai Y, Miyawaki S, Ohtake S, Jinnai I,
Matsuo K, Naoe T, Ohno R.///Blood.;104(12):3507-12. 2004
78.The recent JALSG study for newly diagnosed patients with acute
promyelocytic leukemia (APL).///Ohno R, Asou N; Japan Adult
Leukemia Study Group.///Ann Hematol. 83 Suppl 1:S77-8. 2004
77.Multicenter prospective study of interferon alpha versus allogeneic
stem cell transplantation for patients with new diagnoses of
chronic myelogenous leukemia.///Ohnishi K, Ino A, Kishimoto Y,
Usui N, Shimazaki C, Ohtake S, Taguchi H, Yagasaki F, Tomonaga
M, Hotta T, Ohno R; Japan Adult Leukemia Study Group.///Int J
Hematol. 79(4):345-53. 2004
76.Treatment of acute promyelocytic leukemia: strategy toward
further increase of cure rate./// Ohno R, Asou N, Ohnishi K.///
Leukemia 17(8):1454-1463, 2003.
75.Prediction of response to imatinib by cDNA microarray analysis.
///R Ohno, Y Nakamura./// Seminars in Hematology.40(2):42-49,
2003
74.The percentage of myeloperoxidase-positive blast cells is a strong
independent prognostic factor in acute myeloid leukemia, even in
the patients with normal karyotype.///Matsuo T, Kuriyama K,
Miyazaki Y, Yoshida S, Tomonaga M, Emi N, Kobayashi T, Miyawaki
S, Matsushima T, Shinagawa K, Honda S, Ohno R; Japan Adult
Leukemia Study Group.///Leukemia. 17(8):1538-43.2003
73.Prognosis and prognostic factors for patients with chronic myeloid
leukemia: nontransplant therapy.///Hasford J, Pfirrmann M,
Hehlmann R, Baccarani M, Guilhot F, Mahon FX, Kluin-Nelemans
HC, Ohnishi K, Thaler J, Steegmann JL; Collaborative CML
Prognostic Factors Project Group./// Semin Hematol. 40(1): 4-12.
Review,2003
72.Possible dominant-negative mutation of the SHIP gene in acute
myeloid leukemia./// Luo JM, Yoshida H, Komura S, Ohishi N, Pan
L, Shigeno K, Hanamura I, Miura K, Iida S, Ueda R, Naoe T,Akao Y,
Ohno R, Ohnishi K./// Leukemia. 17(1): 1-8,2003
71.Dual mutations in the AML1 and FLT3 genes are associated with
leukemogenesis in acute myeloblastic leukemia of the M0
subtype./// N Matsuno, M Osato, N Yamashita, M Yanagida, T
Nanri, T Fukushima, T Motoji, S Kusumoto, M Towartari, R Suzuki,
T Naoe, K Nishii, K Shigesada, R Ohno, H Mitsuya, Y Ito and N
Asou./// Leukemia 17:2492-2499, 2003
70.Cytogenetic heterogeneity of acute myeloid leukaemia(AML)with
trilineage dysplasia:Japan Adult Leukaemia Study Group-AML 92
study./// Y.Miyazaki, K.Kuriyama, S.Miyawaki, S.Ohtake,
H.Sakamaki, T.Matsuo, N.Emi, T.Kobayashi, T.Matsushima,
K.Shinagawa, R.Ohno and M.Tomonaga for the Japan Adult
Leukemia Study Group./// Br J Haematology 120:56-62,2003
69.Rapid screening of leukemia fusion transcripts in acute leukemia by
Real-time PCR.///Osumi K, Fukui T, Kiyoi H, Kasai M, Kodera Y,
Kudo K, Kato K, Matsuyama M, Naito K, Tamimoto M, Hirai H,
Saito H, Ohno R, Naoe T. ///Leuk Lymphoma 43: 2291-2299. 2002
68.Efficacy of granulocyte colony-stimulating factor in the treatment
of acute myelogenous leukaemia: a multicentre randomized
study.///Usuki K, Urabe A, Masaoka T, Ohno R, Mizoguchi H,
Hamajima N, Miyazaki T, Niitsu Y, Yoshida Y, Miura A, Shibata A,
Abe T, Miura Y, Ikeda Y, Nomura T, Nagao T, Saitou H, Shirakawa
S, Ohkuma M, Matsuda T, Nakamura T, Horiuchi A, Kuramoto A,
Kimura I, Irino S, Niho Y, Takatsuki K, Tomonaga M, Uchino H,
Takaku F; Gran AML Study Group./// Br J Haematol. 116(1):
103-12,2002
67.Prognostic significance of the null genotype of glutathione
S-transferase-T1 in patients with acute myeloid leukemia:
increased early death after chemotherapy.///Naoe T, Tagawa Y,
Kiyoi H, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Kusumoto S,
Shimazaki C, Saito K, Akiyama H, Motoji T, Nishimura M, Shinagawa
K, Ueda R, Saito H, Ohno R./// Leukemia. 16(2): 203-8, 2002
66.Report of the fifteenth international symposium of the foundation
for promotion of cancer research: new horizons in the diagnosis
and treatment of hematological malignancies based on molecular
genetic features.///Multani PS, Tobinai K, Kakizoe T, Armitage JO,
Ohno R, Sugimura T./// Jpn J Clin Oncol. 32(9): 371-85,2002
65.Prediction of sensitivity to STI571 among chronic myeloid leukemia
patients by genome-wide cDNA microarray analysis./// Kaneta Y,
Kagami Y, Katagiri T, Tsunoda T, Jin-nai I, Taguchi H, Hirai H,
Ohnishi K, Ueda T, Emi N, Tomida A, Tsuruo T, Nakamura Y, Ohno
R./// Jpn J Cancer Res. 93(8): 849-56,2002
64.Arsenic trioxide therapy for relapsed or refractory Japanese
patients with acute promyelocytic leukemia: need for careful
electrocardiogram monitoring./// Ohnishi K, Yoshida H, Shigeno K,
Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H,
Sahara N, Takeshita A, Satoh H, Terada H, Ohno R./// Leukemia.
16(4): 617-22,2002
63.Clinicopathological and prognostic characteristics of
CD56-negative multiple myeloma.///Sahara N, Takeshita A,
Shigeno K, Fujisawa S, Takeshita K, Naito K, Ihara M, Ono T,
Tamashima S, Nara K, Ohnishi K, Ohno R./// Br J Haematol.
117(4): 882-5,2002
62.Prediction of chemosensitivity for patients with acute myeloid
leukemia, according to expression levels of 28 genes selected by
genome-wide complementary DNA microarray analysis.///Okutsu
J, Tsunoda T, Kaneta Y, Katagiri T, Kitahara O, Zembutsu H,
Yanagawa R, Miyawaki S, Kuriyama K, Kubota N, Kimura Y, Kubo K,
Yagasaki F, Higa T, Taguchi H, Tobita T, Akiyama H, Takeshita A,
Wang YH, Motoji T, Ohno R, Nakamura Y./// Mol Cancer Ther.
1(12):1035-42,2002
61.Induction therapy by frequent administration of doxorubicin with
four other drugs, followed by intensive consolidation and
maintenance therapy for adult acute lymphoblastic leukemia: the
JALSG-ALL93 study./// Takeuchi J, Kyo T, Naito K, Sao H,
Takahashi M, Miyawaki S, Kuriyama K, Ohtake S, Yagasaki F,
Murakami H, Asou N, Ino T, Okamoto T, Usui N, Nishimura M,
Shinagawa K, Fukushima T, Taguchi H, Morii T, Mizuta S, Akiyama
H, Nakamura Y, Ohshima T, Ohno R./// Leukemia
16(7):1259-1266,2002
60.Activating mutation of D835 within the activation loop of FLT3 in
human hematologic malignancies.///Yamamoto Y, Kiyoi H, Nakano
Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki
F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T,
Shinagawa K,Takeshita A, Saito H, Ueda R, Ohno R, and Naoe T.
///Blood 97: 2434-2439. 2001
59.Clinicopathologic characteristics of leukemia in Japanese children
and young adults./// Horibe K, Tsukimoto I, Ohno R./// Leukemia
15(8):1256-61,2001
58.Analysis of prognostic factors in newly diagnosed patients with
acute promyelocytic leukemia: the APL92 study of the Japan
Adult Leukemia Study Group (JALSG)./// Asou N, Adachi K,
Tamura U, Kanamaru A, Kageyama S, Hiraoka A, Omoto E,
Akiyama H, Tsubaki K, Saito K, Kuriyama K, Oh H, Kitano K,
Miyawaki S, Takeyama U, Yamada O, Nishikawa K, Takahashi M,
Matsuda S, Ohtake H, Ohno R./// Cancer Chemother Pharmacol
48 Suppl 1:S65-71,2001
57.Morphological diagnosis of the Japan Adult Leukemia Study Group
acute myeloid leukemia protocols: Central review. /// K.Kuriyama,
M.Tomonaga, T.Kobayashi, J.Takeuchi, T.Ohshima, S.Furusawa,
K.Saitoh, R.Ohno for the Japan Adult Leukemia Study Group. ///
Inter J Hematol 73(1):93-99,2001
56. Prolongation of the QT interval and ventricular tachycardia in patients
treated with arsenic trioxide for acute promyelocytic leukemia. ///
Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K,
Shinjyo K, Fujita Y, Matsui H, Takeshita A, Sugiyama S, Satoh H,
Terada H, Ohno R /// Ann Intern Med 033:881-886, 2000
55.Prognostic value of p53 gene mutations and the product
expression in de novo acute myeloid leukemia. ///Nakano Y, Naoe
T, Kiyoi H, Kitamura K, Minami S, Miyawaki S, Asou N, Kuriyama K,
Kusumoto S, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji
T, Shinagawa K, Saito H, Ohno R./// Eur J Haematol 65: 23-31.
2000
54.Poor clinical significance of p53 gene polymorphism in acute
myeloid leukemia. /// Nakano Y, Naoe T, Kiyoi H, Kunishima S,
Minami S, Miyawaki S, Asou N, Kuriyama K, Saito H, Ohno
R.///Leuk Res 24:349-352. 2000,
53.Allogeneic bone marrow transplantation improves the outcome
of de novo AML with trilineage dysplasia(AML-TLD)./// Taguchi J,
Miyazaki Y, Yoshida S, Fukushima T, Moriuchi Y, Jinnai I, Matsuo T,
Kuriyama K, Tomonaga M./// Leukemia 14(11):1861-6,2000
52.How high can we increase complete remission rate in adult acute
myeloid leukemia?/// Ohno R./// Int J Hematol 72(3):272-9,2000
51.Trisomy 11 acute myeloid leukemia: 5 additional cases from the
Japan Adult Leukemia Study Group AML-92 and AML-95
databases./// Suzuki A, Ohyashiki K, Kimura Y, Yamada H, Sano F,
Miyawaki S, Kuriyama K, Ohno R; Japan Adult Leukemia Study
Group./// Int J Hematol 72:466-9,2000
50.Combination chemotherapy with risk factor-adjusted dose
attenuation for high-risk myelodysplastic syndrome and resulting
leukemia in the multicenter study of the Japan Adult Leukemia
Study Group(JALSG): Results of an interim analysis.///
T.Okamoto, A.Knamaru, C.Shimazaki, T.Motoji, Y.Takemoto,
M.Takahashi, T.Fukushima, A.Takeshita, S.Kusumoto, Y.Kishimoto,
S.Yorimitsu, K.Tsukuda, N.Uike, N.Arima, R.Ohno. /// Inter J
Hematol 72(2):200-205,2000
49.Trisomy 10 in Acute Myeloid Leukemia: Three Additional Cases
from the Database of the Japan Adult Leukemia Study Group
(JALSG) AML-92 and AML-95. /// A.Suzuki, Y.Kimura,
K.Ohyashiki, K.Kitano, S.Kageyama, M.Kasai, S.Miyawaki, and
R.Ohno (Japan Adult Leukemia Study Group). /// Cancer Genet
Cytogenet 120(2):141-143,2000
48.Prognostic significance of the cell inhibitor p27 kip1 in acute
myeloid leukemia. ///T.Yokozawa, M.Towatari, H.Iida, K.Takeyama,
M.Tanimoto, H.Kiyoi, T.Motoji, N.sou, K.Saito, M.Takeuchi,
Y.Kobayashi, S.Miyawaki, Y.Kodera, R.Ohno, H.Saito and T.Naoe for
Japan Adult Leukemia Study Group. /// Leukemia 14:28-33,2000
47.Quantitative expression of erythropoietin receptor(EPO-R) on
acute leiukaemia cells: relationships between the amount of EPO-R
and CD phenothpes,in vitro proliferative response,the amount of
other cytokine receptors and clinical prognosis. /// A.Takeshita,
K.Takeshita, M.Higuchi, S.Miyawaki, Y.Takemoto, Y.Kishimoto,
K.Saito, H.Taguchi, K.Kuriyama, Y.Kimura, N.Asou, M.Takahashi,
T.Hotta, A.Kanamaru, R.Ueda, R.Ohno for the Japan Adult
Leukemia Study Group. /// Br J Haematol 108:55-63,2000
46.Prognostic implication of FLT3 and N-RAS gene mutations in
acute myeloid leukemia. ///Kiyoi H, Naoe T, Nakano Y, Yokota S,
Minami S, Miyawaki S, Asou N, Kuriyama K, Jinnai I, Shimazaki C,
Akiyama H, Saito K, Oh H, Motoji T, Omoto E, Saito H, Ohno R,
Ueda R./// Blood 93: 3074-3080. 1999
45.Molecular evolution of acute myeloid leukaemia in relapse: unstable
N-ras and FLT3 genes compared with p53 gene. /// Nakano Y.
Kiyoi H. Miyawaki S. Asou N. Ohno R. Saito H. Naoe T.///Br J
Haematol 104: 659-664. 1999.
44.Infectious complications during remission induction therapy in 577
patients with acute myeloid leukemia in the Japan Adult Leukemia
Study Group studies between 1987 and 1991. ///M.Yoshida,
K.Tsubaki, T.Kobayashi, M.Tanimoto, K.Kuriyama, H.Murakami,
S.Minami, A.Hiraoka, I.Takahashi, T.Naoe, N.Asou, S.Kageyama,
M.Tomonaga, H.Saito, R.Ohno, for the Japan Adult Leukemia Study
Group. /// Inter J Hematol 70:261-267,1999
43.No beneficial effect from addition of etoposide to daunorubicin,
cytarabine, and 6- mercaptopurine in individualized induction
therapy of adult acute myeloid leukemia: the JALSG-AML92
study. /// S.Miyawaki, M.Tanimoto, T.Kobayashi, S.Minami,
J.Tamura, E.Omoto, K.Kuriyama, K.Hatake, K.Saito, A.Kanamaru,
H.Oh, S.Ohtake, N.Asou, H.Sakamaki, O.Yamada, I.Jinnnai, K.Tsubaki,
K.Takeyama, A.Hiraoka, S.Matsuda, M.Takahashi, C.Shimazaki,
K.Adachi, S.Kageyama, T.Sakura, R.Ohno, for the Japan Adult
Leukemia Study Group. ///Inter J Hematol 70:97-104,1999
42.Comparison of leukopenia between cytarabine and behenoyl
cytarabine in JALSG AML-89 consolidation therapy.
///S.Miyawaki, T.Kobayashi, M.Tanimoto, K.Kuriyama, H.Murakami,
M.Yoshida, S.Minami, K.Minato, K.Tsubaki, E.Omoto, H.Oh, I.Jinnai,
H.Sakamaki, A.Hiraoka, A.Kanamaru, I.Takahashi, K.Saito, T.Naoe,
O.Yamada, N.Asou, S.Kageyama, N.Emi, T.Ueda, M.Tomonaga,
H.Saito, R.Ueda, R.Ohno, for the Japan Adult Leukemia Study
Group. ///Inter J Hematol 70:56-57,1999
41.Granulocyte colony-stimulating factor, granulocyte-macrophage
colony-stimulating factor and macrophage colony-stimulating factor
in the treatment of acute myeloid leukemia and acute lymphoblastic
leukemia.///R.Ohno.///Leuk Res
22(12):1143-54,1998
40.Multicenter cooperative study group in hematology in Japan: the
10-year history and role of the Japan Adult Leukemia Study Group
in Japan./// Ohno R./// Int J Hematol67(3):213-9,1998
39.Cooperative oncology groups in Japan: experience from the Japan
Adult Leukemia Study Group./// Ohno R./// Cancer Chemother
Pharmacol42 Suppl:S93-7,1998
38.Response-oriented individualized indeuction therapy followed by
intensive consolidation and maintenance for adult patients with
acute lymphoblastic leukemia: Thed ALL-87 Study of the Japan
Adult Leukemia Study Group. /// M.tanimoto, S.Miyawaki, T.Ino,
T.Kyo, H.Sakamaki, T.Naoe, A.Hiraoka, N.Asou, T.Ohshima,
K.Tsubaki, K.Kuriyama, T.Ueda, S.MInami, K.Okabe,H.Saito,
H.Murakami, M.Hirano, H.Dohy, Y.Onozawa, H.Suzuki, R.Ohno. ///
Inter J Hematol 68:421-429,1998
37.Response-oriented individualized induction therapy with six drugs
followed by four courses of intensive consolidation, 1 year
maintenance and intensification therapy: the ALL90 study of the
Japan Adult Leukemia Study Group. /// T.Ueda, S.Miyawaki,
N.Asou, Y.Kuraishi, A.Hiraoka, K.Kuriyama, S.Minami, T.Ohsima,
T.Ino, J.Tamura, A.Kanamaru, K.Nishikawa, M.Tanimoto, H.OH,
K.saito, K.Nagata, T.Naoe, O.Yamada, Y.Urasaki, T.Sakura, R.Ohno.
/// Inter J Hematol 68:279-289,1998
36.Chemotherapy vs HLA-indentical sibling bone marrow transplants
for adults with acute lymphoblastic leukemia in first remission. ///
H.Oh, RP Gale, M-J Zhang, JR Passweg, T Ino, H Murakami, R
Ohno, PA Rowlings, KA Sobocinski, M Tanimoto, M Tomonaga, DJ
Weisdorf and MM Horowitz. /// Bone Marrow Transplant.
22:253-257,1998
35.Analysis of prognostic factors in newly diagnosed acute
promyelocytic leukemia treated with all-trans retinoic acid and
chemotherapy. /// N.Asou, K.Adachi, J.Tamura, A.Kanamaru,
S.Kageyama, A.Hiraoka, E.Omoto, H.Akiyama, K.Tsubaki, K.Saito,
K.Kuriyama, H.Oh, K.Kitano, S.Miyawaki, K.Takeyama, O.Yamada,
K.Nishikawa, M.Takahashi, S.Matsuda, S.Ohtake, H.Suzushima,
N.Emi, R.Ohno and the Japan Adult Leukemia Study Group
(JALSG)./// Journal of Clinical Oncology 16(1):78-85,1998
34.Internal trandem duplication of FLT3 associated with leukocytosis
in acute promyelocytic leukemia. /// H.Kiyoi, T.Naoe, S.Yokota,
M.Nakao, S.Minami, K.Kuriyama, A.Takeshita, K.Saito, S.Hasegawa,
S.Shimodaira, J.tamura, C.Shimazaki, K.Matsue, H.Kobayashi,
N.Arima, R.Suzuki, H.Morishita, H.Saito, R.Ueda, R.Ohno and the
Leukemia Study Group of the Ministry of Health and
Welfare(Kohseisho). /// Leukemia 11:1447-1452,1997
33.All-trans retinoic acid therapy for newly diagnosed acute
promyelocytic leukemia: comparison with intensive chemotherapy.
/// N.Asou, K.Adachi, J.Tamura, A.Kanamaru, S.Kageyama,
A.Hiraoka, E.Omoto, H.Sakamaki, K.Tsubaki, K.Saito, R.Ohno and
the Japan Adult Leukemia Study Group (JALSG). /// Cancer
Chemother Pharmacol 40:S30-S35,1997
32.Human urinary macrophage colony-stimulating factor reduces the
incidence and duration of febrile neutropenia and shortens the
period required to finish three courses of intensive consolidation
therapy in acute myeloid leukemia:a double-blind controlled study.
/// R.Ohno, S.Miyawaki, K.Hatake, K.Kuriyama, K.Saito,
A.Kanamaru, T.Kobayashi, Y.Kodera, K.Nishikawa, S.Matsuda,
O.Yamada, E.Omoto, H.Takeyama, K.Tsukuda, N.Asou, M.Tanimoto,
H.Shiozaki, M.Tomonaga, T.Masaoka, Y.Miura, F.Takaku, Y.Ohashi
and K.Motoyoshi. /// Journal of Clinical Oncology
15(8):2954-2965,1997
31.Treatment with a new synthetic retinoid, Am80,of acute
promyelocytic leukemia relapsed from complete remission induced
by all-trans retinoic acid. /// T.Tobita, A.Takeshita, K.Kitamura,
K.Ohnishi, M.Yanagi, A.Hiraoka, T.Karasuno, M.Takeuchi, S.Miyawaki,
R.Ueda, T.Naoe and R.Ohno. /// Blood90(3):967-973,1997
30.Morpholosgical subtyping of acute myeloid leukemia with
maturation (AML-M2): homogeneous pink-coloared cytoplasm of
mature neutrophils is most characteristic of AML-M2 with t(8;21).
/// H.Nakamura, K.Kuriyama, N.Sadamori, M.Mine, T.Itoyama,
I.Sasagawa, K.Matsumoto, Y.Tsuji, N.Asou, S.I.Kageyama,
H.Sakamaki, N.Emi, R.Ohno and M.Tomonaga. ///
Leukemia11:651-655,1997
29.Case-control study of leukemia and diagnostic radiation exposure.
/// H.Yuasa, N.Hamajima, R.Ueda, R.Ohno, N.Asou, A.Utsunomiya,
M.Ogura, N.Takigawa, T.Ueda, A.Hiraoka, S.Matsuda, Y.Kuraishi,
K.Nishikawa, N.Uike, A.Takeshita, Y.Takemoto, C.Shimazaki,
H.Sakamaki, T.Ino, T.Matsushima, K.Kuriyama, H.Hirai, T.Naoe,
K.Tsubaki, M.Takahashi, K.Takeyama, Y.Morishima, K.Itoh. /// Inter
J Haematol 65:251-261,1997
28.Application of fluorescence in situ hybridization to detect residual
leukemic cells with 9;22 and 15;17 translocations. /// K.Tanaka,
M.Arif, M.Eguchi, T.S.Kumaravel, R.Ueda, R.Ohno, K.Iwato, T.Kyo,
H.Dohy and N.Kamada. /// Leukemia11:436-440,1997
27.Inactivation of multiple tumor-suppressor genes involved in
negative regulation of the cell cycle, MTS1/p161NK4A CDKN2,
MTS2/p151NK4B, p53, and Rb genes in primary lymphoid
malignancies. /// A.Hangaishi, S.Ogawa, N.Imamura, S.Miyawaki,
Y.Miura, N.Uike, C.Shimazaki, N.Emi, K.Takeyama, S.Hirosawa,
N.Kamada, Y.Kobayashi, Y.Takemoto, T.Kitani, K.Toyama, S.Ohtake,
Y.Yazaki, R.Ueda, H.Hirai. /// Blood 87:4949-58,1996
26.Expression of costimulatory molecules in human leukemias. ///
N.Hirano, T.Takahashi, T.Takahashi, S.Ohtake, K.Hirashima, N.Emi,
K.Saito, M.Hirano, K.Shinohara, M.Takeuchi, F.Taketazu, S.Tsunoda,
M.Ogura, M.Omine, T.Sito, Y.Yazaki, R.Ueda, H.Hirai. ///
Leukemia10:1168-76,1996
25.Successful treatment of relapse of acute promyelocytic leukemia
with a new synthetic retinoid, Am80. /// A.Takeshita, Y.Shibata,
K.Shinjo, M.Yanagi, T.Tobita, K.Ohnishi, S.Miyawaki, K.Shudo and
R.Ohno. /// Annals of Internal Medicine 124:893-896,1996
24.Randomized trials between behenoyl cytarabine and cytarabine in
combination induction and consolidation therapy, and with or
without ubenimex after maintenance/intensification therapy in
adult acute myeloid leukemia. /// T.Kobayashi, S.Miyawaki,
M.Tanimoto, K.Kuriyama, H.Murakami, M.Yoshida, S.Minami,
K.Tsubaki, E.Ohmoto, H.Oh, I.Jinnai, H.Sakamaki, A.Hiraoka,
A.Kanamaru, I.Takahashi, K.Saito, T.Naoe, O.Yamada, N.Asou,
S.Kageyama, N.Emi, A.Matsuoka, M.Tomonaga, H.Saito, R.Ueda, and
R.Ohno for the Japan Adult Leukemia Study Group(JALSG). ///
Journal of Clinical Oncology 14:204-213,1996
23.Recent progress in the treatment of adult acute leukemia in
Japan. /// R.Ohno for the Japan Adalt Leukemia Study Group
(JALSG). /// Cancer Chemotherapy 10:73-79,1995
22.Significant reduction of medical costs by differentiation therapy
with all-trans retinoic acid during remission induction of newly
diagnosed patients with acute promyelocytic leukemia. ///
A.Takeshita, H.Sakamaki, S.Miyawaki, T.Kobayashi, K.Kuriyama,
O.Yamada, H.Oh, T.Takenaka, N.Asou, R.Ohno and the Japan Adult
Leukemia Sutdy Group (JALSG). /// Cancer76:602-608,1995
21.Isoforms of PML-retinoic acid receptor alpha fused transcripts
affect neither clinical features of acute promyelocytic leukemia
nor prognosis after treatment with all-trans retinoic acid. ///
H.Fukutani, T.Naoe, R.Ohno, H.Yoshida, S.Miyawaki, C.Simazaki,
T.Miyake, Y.Nakayama, H.Kobayashi, S.Goto, A.Takeshita,
S.Kobayashi, Y.Kato, K.Shiraishi, M.Sasada, S.Ohtake, H.Murakami,
M.Kobayashi, N.Endo, H.Shindo, K.Matsushita, S.Hasegawa, K.Tsuji,
Y.Ueda, N.Tominaga, H.Furuya, Y.Inoue, J.Takeuchi, H.Morishita,
H.Iida, and the Leukemia Study Group of the Ministry of Health
and Welfare(Kohseisho). /// Leukemia9:1478-1482,1995
20.A randomized trial comparing interferon-alpha with busulfan for
newly diagnosed chronic myelogenous leukemia in chronic phase.
/// K.Ohnishi, R.Ohno, M.Tomonaga, N.Kamada, K.Onozawa,
A.Kuramoto, H.Dohy, H.Mizoguchi, S.Miyawaki, K.Tsubaki, Y.Miura,
M.Omine, T.Kobayashi, T.Naoe, T.Ohshima, K.Hirashima, S.Ohtake,
I,Takahashi, Y.Morishima, K.Naito, N.Asou, M.Tanimoto, A.Sakuma,
K.Yamada and the Kouseisho Lukemia Study Group. /// Blood
86:906-916,1995
19.All-trans retinoic acid for the treatment of newly diagnosed acute
promyelocytic leukemia. /// A.Kanamaru and R.Ohno. /// Blood
86:1644-45,1995
18.Prognostic significance of the RT-PCR assay of PML-RARA
transcripts in acute promyelocytic leukemia. ///H.Fukutani,
T.Naoe, R.Ohno , H.Yoshida, H.Kiyoi, S.Miyawaki, H.Morishita,
F.Sano, H.Kamibayashi, K.Matsue, T.Miyake, S.Hasegawa, Y.Ueda,
T.Kato, H.Kobayashi, C.Shimazaki, M.Kobayashi, R.Kurane,
H.Sakota, K.Masaki, T.Wakayama, K.Tohyama, Y.Nonaka, H.Natori
and the leukemia Study Group of the Ministry of Health and
Welfare (Kouseisho). ///Leukemia9:588-593,1995
17.All-trans retinoic acid for the treatment of newly diagnosed acute
promyelocytic leukemia. /// A.Kanamaru, Y.Takemoto, M.Tanimoto,
H.Murakami, N.Asou, T.Kobayashi, K.Kuriyama, E.Ohmoto,
H.Sakamaki, K.Tsubaki, A.Hiraoka, O.Yamada, H.Oh, K.Saito,
S.Matsuda, K.Minato, T.Ueda, R.Ohno and the Japan Adult
Leukemia Study Group (JALSG). /// Blood 85:1202-1206,1995
16.G-CSF in the treatment of acute myeloid leukemia:is it safe? ///
R.Ohno. /// Leukemia and Lymphoma 11(Suppl.2):15-19.1994
15.All-trans retinoic acid therapy in relapsed/refractory or newly
diagnosed acute promyelocytic leukemia(APL) in Japan. ///
R.Ohno, K.Ohnishi, A.Takeshita, M.Tanimoto, H.Murakami,
A.Kanamaru, N.Asou, T.Kobayashi, K.Kuriyama, E.Ohmoto,
H.Sakamaki, K.Tsubaki, A.Hiraoka, O.Yamada, H.Oh, S.Furusawa,
S.Matsuda and T.Naoe. /// Leukemia 8(suppl.3):S64-S69,1994
14.Differentiation therapy of myelodysplastic syndromes with retinoic
acid. ///R.Ohno. /// Leukemia & Lymphoma 14:401-409,1994
13.A double-blind controlled study of granulocyte colony-stimulating
factor started two days before induction chemotherapy in
refractory acute myeloid leukemia. /// R.Ohno, T.Naoe,
A.Kanamaru, M.Yoshida, A.Hiraoka, T.Kobayashi, T.Ueda, S.Minami,
Y.Morishima, Y.Saito, S.Furusawa, K.Imai, Y.Takemoto, Y.Miura,
H.Teshima, N.Hamajima and the Kohseisho Leukemia Study Group.
/// Blood 83:2086-2092,1994
12.Poor response to intensive chemotherapy in de novo acute
myeloid leukaemia with trilineage mylodysplasia. /// K.Kuriyama,
M.Tomonaga, T.Matsuo, T.Kobayashi, H.Miwa, S.Shirakawa,
M.Tanimoto, K.Adachi, N.Emi, A.Hiraoka, N.Tominaga, K.Imai, N.Asou,
K.Tsubaki, I.Takahashi, S.Minami, M.Yoshida, H.Murakami, K.Minato,
T.Ohshima, S.Furusawa, R.Ohno and the Japan Adult Leukemia Study
Group (JALSG). /// Br J Haematol 86:767-773,1994
11.Japanese B cell chronic Lymphocytic leukemia:a cytogenetic and
molecular biological study. /// H.Asou, M.Takechi, K.Tanaka,
S.Tashiro, H.Dohy, R.Ohno and N.Kamada. /// Br J Haematol
85:492-497,1993
10.A randomized controlled study of granulocyte colony stimulating
factor after intensive induction and consolidation therapy in
patients with acute lymphoblastic leukemia. /// R.Ohno,
M.Tomonaga, T.Ohshima, T.Masaoka, N.Asou, H.Oh, K.Nishikawa,
A.Kanamaru, H.Murakami, S.Furusawa, M.Hirano, K.Tsubaki, K.Imai,
T.Ueda, Y.Kuraishi, N.Ogawa, Japan Adult Leukemia Study Group
(JALSG). /// Inter J Hematol 58:73-81,1993
9.Treatment of acute promyelocytic leukemia with all-trans retinoic
acid and molecular analysis of the t(15;17) translocation. ///
T.Naoe, H.Fukutani, H.Yoshida, S.Yamamori, R.Ohno and Kouseishou
APL Study Group. /// Cancer Chemotherapy 8:166-171,1993
8.Randomized study of intensive individualized induction therapy with
or without vincristine and of maintenance/intensification therapy
in adult acute myeloid leukemia. /// R.Ohno, T.Kobayashi,
M.Tanimoto, A.Hiraoka, K.Imai, K.Fujimoto, M.Tomonaga, K.Tsubaki,
E.Ohmoto, Y.Kodera, H.Murakami, M.Yoshida and Japan Adult
Leukmemia Study Group (JALSG). /// Acute
Leukemias:645-649,1993
7.Multi-institutional study of all-trans retinoic acid as a
differentiation therapy of refractory acute promyelocytic leukemia.
/// R.Ohno, H.Yoshida, H.Fukutani, T.Naoe, T.Ohshima, T.Kyo,
N.Endoh, T.Fujimoto, T.Kobayashi, A.Hiraoka, H.Mizoguchi, Y.Kodera,
H.Suzuki, M.Hirano, H.Akiyama, N.Aoki, H.Shindo, S.Yokomaku and
the Leukemia Study Group of the Ministry of Health and Welfare.
/// Leukemia 7:1722-1727,1993
6.Randomized study of individualized induction therapy with or
without vincristine, and of maintenance-intensification therapy
between 4 or 12 courses in adult acute myeloid leukemia. AML-87
study of the Japan Adult Leukemia Study Group /// R.Ohno,
T.Kobayashi, M.Tanimoto, A.Hiraoka, K.Imai, N.Asou, M.Tomonaga,
K.Tsubaki, I.Takahashi, Y.Kodera, M.Yoshida, H.Murakami, T.Naoe,
M.Shimoyama, T.Tukada, T.Takeo, H.Teshima, Y.Onozawa,
K.Fujimoto, K.Kuriyama, A.Horiuchi, I.Kimura, S.Minami, Y.Miura,
S.Kageyama, T.Tahara, T.Masaoka, S.Shirakawa and H.Saito. ///
Cancer 71:3888-3895,1993
5.Current progress in the treatment of adult acute leukemia in
Japan. /// R.Ohno. /// Japanese Journal of Clinical Oncology
22:85-97,1993
4.Treatment of myelodysplastic syndromes with all-trans retinoic
acid. /// R.Ohno, T.Naoe, M.Hirano, M.Kobayashi, H.Hirai, K.Tubaki,
H.Oh and the Leukemia Study Group of Ministry of Heath and
Welfare. /// Blood 81:1152-1154,1993
3.No increase of leukemia relapse in newly diagnosed patients with
acute myeloidleukemia who received granulocyte colony-
stimulating factor for life-threatening infection during remission
induction and consolidation therapy. /// R.Ohno, A.Hiraoka,
M.Tanimoto, N.Asou, K.Kuriyama, T.Kobayashi, H.Teshima, H.Saito,
K.Fujimoto and Japan Adult Leukemia Study Group (JALSG).///
Blood 81:561-562,1993
2.Randomized study of individualized induction therapy with or
without VCR, and of maintenance 4 or 12 courses in adult AML:
JALSG-AML87 /// R.Ohno, T.Kobayashi, Y.Morishima, A.Hiraoka,
N.Naoe and Japan Adult Leukemia Study Group (JALSG). ///
Leukemia 6(Supplement 2):92-95,1992
1.Effect of granulocyte colony-stimulating factor after intensive
induction therapy in relapsed or refractory acute leukemia: ///
R.Ohno, M.Tomonaga, T.Kobayashi, A.Kanamura, S.Shirakawa,
T.Masaoka, M.Omine, H.Oh, T.Nomura, Y.Nakayama, Y.Yoshida,
A.B.Miura, Y.Morishima, H.Dohy, Y.Niho, N.Hamajima and F.Takaku.
/// N Eng J Med 323:871-877,1990